✓ Medically reviewed by · Last reviewed: May 2026
Pharmacy Researcher · 8 years experience
Pharmacy researcher with 8 years reviewing clinical drug information, generic formulation equivalence, and international pharmaceutical standards. Focuses on patient-facing accuracy in medication education.
Quick Answer
Rogaine and Tugain contain the identical active molecule — minoxidil — in topical solution or foam at 2% (women) or 5% (men) concentrations. Both extend the hair-cycle anagen (growth) phase and produce visible regrowth in roughly 40–60% of users at 4–6 months. The differences are economic and supply chain: Kenvue’s (formerly Pfizer’s) Rogaine US retail pricing is approximately $25–$40 per month for the 5% foam. Cipla’s Tugain ships worldwide from MedsBase — at roughly $8–$15 per month. Same molecule, ~3× price gap.
Minoxidil has the unusual distinction of being an FDA-approved over-the-counter drug for hair loss in the United States since 1988. The molecule was originally developed by Upjohn (now Pfizer) as an oral antihypertensive in 1979 and produced hypertrichosis (unwanted body hair growth) as a side effect in a substantial fraction of treated patients. Topical reformulation for treatment of androgenetic alopecia followed; FDA approval for the 2% solution came in 1988 and for the 5% solution in 1997. The 5% foam followed in 2006.
Pfizer’s original Rogaine brand has changed corporate ownership multiple times (Pharmacia, Pfizer, Johnson & Johnson, Kenvue) but the molecule, dose, and labelling have not changed. The Olsen et al. 5-year extension data1 established durable efficacy with continuous use, and a substantial body of subsequent literature has confirmed the response profile.
Outside the US, generic minoxidil has been widely available since the early 2000s. Tugain, manufactured by Cipla Ltd in Mumbai — one of the largest WHO-GMP-certified generic manufacturers globally — is among the most widely distributed generic minoxidil products in the global market. MedsBase carries both the Tugain Solution and Tugain Foam variants.
TL;DR comparison table
| Rogaine (brand) | Tugain (generic) | |
|---|---|---|
| Active ingredient | Minoxidil | Minoxidil |
| Concentrations | 2% (women), 5% (men) | 2%, 5%, 10% (extended range) |
| Forms | Solution + 5% foam | Solution + foam |
| Manufacturer | Kenvue (formerly Pfizer/J&J) | Cipla Ltd (WHO-GMP, Mumbai) |
| Application | 1Â mL or half-capful foam twice daily | Same |
| Onset of clinical effect | 3–4 months: reduced shedding; 6–12 months: visible regrowth | Same |
| Response rate | ~40–60% see meaningful regrowth at 5% strength | Same molecule, same expected response |
| Typical 2026 monthly cost | ~$25–$40 (5% foam, US retail) | ~$8–$15 on MedsBase |
| Regulatory status | FDA-approved OTC (US, no prescription) | WHO-GMP, not FDA-registered |
How minoxidil works
Minoxidil’s hair-growth mechanism is not fully understood despite decades of clinical use. The current consensus model:
- Vasodilation: minoxidil is a potassium-channel opener in vascular smooth muscle, producing local vasodilation in scalp microvasculature and improving follicular blood supply.
- Prolonged anagen phase: in the hair-growth cycle, the anagen (growth) phase normally lasts 2–7 years before the follicle enters catagen and telogen. Minoxidil extends anagen duration, producing longer and thicker individual hair shafts and reducing the proportion of follicles in the resting state at any given time.
- Possible direct effect on dermal papilla cells: in vitro evidence suggests minoxidil and its sulfated metabolite minoxidil sulfate stimulate follicular keratinocyte proliferation independently of vasodilation.
Notably, minoxidil’s mechanism is independent of DHT (androgen) signalling — the pathway that finasteride and dutasteride target. This is why combining the two drug classes produces additive response, as documented in multiple comparative trials.
Doses, forms, and concentrations
Standard regimens:
- Men: 5% solution or 5% foam, applied to dry scalp twice daily (1Â mL solution or half a capful of foam per application).
- Women: 2% solution twice daily, or 5% foam once daily (FDA-approved 2014 alternative dosing).
- Tugain 10% (export-market only): not standard recommended; double-strength formulation used by some men who don’t respond adequately to 5%. Higher rates of local irritation and unwanted facial hair growth.
Foam vs solution choice is largely cosmetic preference. The foam dries faster, leaves no residue, and is easier to apply with one hand. The solution penetrates somewhat differently and remains the formulation most extensively studied in trials. Both are approximately equipotent at the same minoxidil concentration.
Bioequivalence considerations for topical products
Topical generic equivalence is regulated differently from oral generics. FDA requires that topical products demonstrate equivalent active ingredient release rates, equivalent dermatopharmacokinetics where applicable, or in some cases comparative clinical efficacy studies. The 5% minoxidil topical strength has been the subject of multiple comparative studies between branded Rogaine and generic minoxidil products with consistent equivalence findings.
The Tugain formulation, like Rogaine, uses minoxidil dissolved in a base of propylene glycol, ethanol, and water. Inactive-ingredient ratios differ between manufacturers, which can affect tolerability for users sensitive to specific solvents (propylene glycol sensitivity is the most common cause of local irritation) but does not affect the minoxidil’s primary mechanism.
Price comparison
| Channel | 5% minoxidil, monthly supply |
|---|---|
| Rogaine 5% Foam, US retail | ~$25–$40 |
| Costco Kirkland Signature 5% solution | ~$8–$12 |
| Amazon Basics 5% minoxidil | ~$10–$15 |
| Tugain Solution 5%, MedsBase | ~$8–$12 |
| Tugain Foam 5%, MedsBase | ~$10–$15 |
The branded-vs-generic gap is smaller for minoxidil than for the prescription PDE5 inhibitors because the molecule has been OTC for nearly 40 years and US pricing pressure from generic Costco and Amazon Basics minoxidil has already eroded much of the Rogaine premium. The Tugain pricing remains the most competitive globally available option.
Side effects: same across all manufacturers
Topical minoxidil side effects are predominantly local:
- Scalp irritation, itching, or contact dermatitis (~2–5%) — usually caused by the propylene glycol vehicle rather than minoxidil itself. Switching to a different formulation (e.g., propylene-glycol-free foam) often resolves it.
- Increased shedding in first 2–8 weeks (the “minoxidil shed”) — represents synchronisation of follicles entering anagen, and is followed by improved density. Not a sign of treatment failure.
- Unwanted facial hair growth in women (rare at 5%, more common at 10%) — occurs when the topical product runs down the forehead or is transferred from the scalp to facial areas. Application technique matters.
- Headache or dizziness (very rare, generally only at supratherapeutic doses) — reflects systemic absorption when applied excessively or to broken skin.
Serious systemic effects (tachycardia, fluid retention) are extremely rare with topical 2–5% formulations applied at recommended doses. The oral 2.5–5 mg minoxidil tablet form for hair loss, prescribed off-label by some physicians, has a different systemic-effect profile and is outside the scope of this comparison.
Contraindications and cautions
Topical minoxidil should not be used in:
- Pregnancy or breastfeeding (no demonstrated safety; some systemic absorption occurs)
- Children under 18 (off-label data exists but is limited)
- Scalp with active inflammation, open wounds, or sunburn (systemic absorption increased)
- Known propylene-glycol sensitivity (switch to PG-free foam formulation)
Avoid contact with eyes, mouth, and mucous membranes. Wash hands after application.
Manufacturer disclosure: who makes Tugain?
Tugain is manufactured by Cipla Ltd, headquartered in Mumbai — one of the largest WHO-GMP-certified generic manufacturers globally, supplying medicines to over 80 countries. Cipla holds approvals from US FDA, UK MHRA, WHO Prequalification, and most national regulatory bodies. Per-batch finished-product release for Tugain includes HPLC content uniformity assay for minoxidil concentration, propylene-glycol content verification, and pH testing. Certificates of Analysis are available on request through MedsBase customer support.
How to order Tugain from MedsBase
Tugain ships worldwide from MedsBase in discreet packaging (plain envelope, no medication name on the exterior). Payment via crypto (USDT, BTC, ETH via Plisio), credit card via a regulated crypto on-ramp, or SEPA where available. See our credit card payment guide. Orders are covered by the MedsBase Reshipment Assurance Policy. Browse Tugain Solution or Tugain Foam.
Combining minoxidil with finasteride
The single most-studied combination for male androgenetic alopecia is finasteride 1 mg oral + minoxidil 5% topical. The two drugs target independent mechanisms — finasteride reduces DHT-driven follicular miniaturisation, minoxidil extends anagen phase — producing additive response. Multiple randomised trials have demonstrated superior outcomes for the combination versus either monotherapy.
The MedsBase Hair Loss Stack bundles Finpecia (finasteride 1 mg) + Tugain Foam (minoxidil 5%) at the standard combination doses for cost-efficient long-term use. For the finasteride-specific brand-vs-generic comparison, see Propecia vs Finpecia. For dutasteride (the more potent 5α-reductase inhibitor used when finasteride response is inadequate), see Avodart vs Dutas.
Pricing context: The brand-vs-generic price comparison on this page is one entry in MedsBase’s broader Brand-vs-Generic Medication Pricing Index — a quarterly-updated reference covering 15 brand-vs-generic pairs across ED, GLP-1, hair-loss, PrEP, and cosmetic clusters, with full methodology and citation disclosure.
Frequently Asked Questions
Is Tugain literally the same drug as Rogaine?
Yes. Both contain minoxidil as the active ingredient at the same labelled concentrations (2%, 5%). The mechanism, onset, response rate, and side-effect profile are pharmacologically identical. The differences are the manufacturer, the inactive solvents (propylene glycol, ethanol, water in different ratios), and the price.
Is Tugain FDA-approved?
No. Tugain is not registered with the US FDA because it is not marketed in the United States. However, Cipla manufactures Tugain under WHO-GMP certification. Generic minoxidil products that ARE sold OTC in US retail are FDA-approved equivalents to Rogaine.
How long until I see results?
Reduced shedding becomes noticeable around month 3–4. Visible regrowth in miniaturised follicles takes 6–12 months. Maximum effect is observed around month 12–18 of continuous twice-daily use. This timeline is intrinsic to the hair-growth cycle, not the brand — Tugain and Rogaine produce results on the same schedule.
What happens if I stop using minoxidil?
Within 3–6 months of discontinuation, the hair gained during treatment is lost. Minoxidil maintains its effect only as long as you keep using it; there is no “cure” window. This applies equally to Tugain and Rogaine because the mechanism is identical.
Should I use 5% solution or 5% foam?
Both deliver equivalent minoxidil at equivalent concentration. The foam dries faster, leaves no residue, and is easier for one-handed application. The solution is the formulation studied in most original trials. Choose based on cosmetic preference and any propylene-glycol sensitivity (foam typically has less PG).
Will the “minoxidil shed” happen with Tugain too?
Yes. The 2–8 week shedding episode after starting minoxidil represents synchronisation of follicles entering anagen phase as the local pharmacology shifts. It is a property of the molecule and the hair cycle, not the brand. It is followed by improved overall density.
Can I use Tugain 10%? Is it more effective?
Tugain 10% exceeds the standard 5% labelled maximum and is not FDA-approved or recommended as routine. Some men who do not respond adequately to 5% titrate up to 10% under supervision. Local irritation and unwanted hair growth in non-target areas (forehead, temples, ears) become more common at the higher concentration. 5% is the standard.
Should I combine Tugain with Finpecia?
The most-studied combination for male androgenetic alopecia is exactly this: oral finasteride 1Â mg + topical minoxidil 5% twice daily. Combined response rates exceed either monotherapy in randomised trials. The MedsBase Hair Loss Stack bundles both at standard combination doses.
Sources
- Olsen EA, Dunlap FE, Funicella T, et al. A randomized clinical trial of 5% topical minoxidil versus 2% topical minoxidil and placebo in the treatment of androgenetic alopecia in men. Journal of the American Academy of Dermatology. 2002;47(3):377–385.
- US Food and Drug Administration. Minoxidil topical solution (Rogaine) OTC monograph history, 1988–1997.
- Olsen EA, Whiting D, Bergfeld W, et al. A multicenter, randomized, placebo-controlled, double-blind clinical trial of a novel formulation of 5% minoxidil topical foam versus placebo in the treatment of androgenetic alopecia in men. Journal of the American Academy of Dermatology. 2007;57(5):767–774.
- Cipla Ltd. WHO-GMP certification under the Indian Central Drugs Standard Control Organisation; multiple national regulatory approvals.
Last clinically reviewed: 18 May 2026.
Written by
Sophie ChenPharmaceutical Content Researcher · 8 years experience
Sophie Chen is a pharmaceutical content researcher with 8 years covering generic medication access and clinical pharmacology. She specialises in international regulatory frameworks, bioequivalence standards, and patient-facing education on therapeutic drug classes. She is not a clinician.